Cerebrospinal fluid choline levels are decreased in Parkinson's disease

Manyam, Bala V.; Giacobini, Ezio; Colliver, Jerry A.

doi:10.1002/ana.410270616

Cited by 21 publications

(7 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several authors have described AChE activity in the CSF from PD patients Unchanged (Direnfeld et al, 1984;Jolkkonen et al, 1986;Zubenko et at., 1986;Sirvi6 et al, 1987;Manyam et al, 1990) or increased (Ruberg et al, 1986). In the present study, the levels of AChE of PD patients did not differ from other groups, although the values were lowest for the demented PD patients and for the most severe stage of the disease.…”

Section: Discussionmentioning

confidence: 95%

Neurochemical markers in the cerebrospinal fluid of patients with Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis and normal controls

Hartikainen¹,

Reinikainen²,

Soininen³

et al. 1992

J Neural Transm Gen Sect

View full text Add to dashboard Cite

Several neurotransmitter markers were investigated in the cerebrospinal fluid (CSF) from patients with Alzheimer's disease (AD) (n = 27), Parkinson's disease (PD) (n = 35) and ALS (n = 26) and from control subjects (n = 34) to compare the possible alterations in the biochemical profiles of these different neurodegenerative diseases. The main proportion of the patients represented an early phase of the illness at the time of the diagnosis. Correlations of the degree of dementia and the stage of the disease with CSF measures were evaluated. The CSF levels of somatostatin like-immunoreactivity (SLI) were significantly reduced in AD patients when compared with those of normals and ALS patients. The CSF concentrations of homovanillic acid (HVA) were significantly decreased for PD patients and the decrease focused on the non-demented patients. A trend of decreasing HVA values towards the most advanced stage of Parkinson's disease assessed by Webster's scale was also displayed. The content of 3-methoxy-4-hydroxyphenylglycol (MHPG) in the CSF was higher for ALS patients than for other groups. The lowest 5-hydroxy-indoleacetic acid (5HIAA) levels were observed in the PD group and the lowest acetylcholinesterase (AChE) activities were found in the PD patients with the most severe disease. Changes in CSF measures were too subtle to be beneficial for diagnostic purposes, but adequate for reflecting the different neurochemical profiles of these three degenerative neurological disorders.

show abstract

Section: Discussionmentioning

confidence: 95%

Neurochemical markers in the cerebrospinal fluid of patients with Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis and normal controls

Hartikainen¹,

Reinikainen²,

Soininen³

et al. 1992

J Neural Transm Gen Sect

View full text Add to dashboard Cite

show abstract

“…In humans, choline levels in the CSF are decreased in Parkinson's and Huntington's diseases (Manyam et al . ,b) and increased in patients with dementia of the Alzheimer type (Elble et al . ).…”

Section: Discussionmentioning

confidence: 99%

Choline‐mediated modulation of hippocampal sharp wave–ripple complexes in vitro

Fischer

Both

Draguhn

et al. 2014

Journal of Neurochemistry

View full text Add to dashboard Cite

The cholinergic system is critically involved in the modulation of cognitive functions, including learning and memory. Acetylcholine acts through muscarinic (mAChRs) and nicotinic receptors (nAChRs), which are both abundantly expressed in the hippocampus. Previous evidence indicates that choline, the precursor and degradation product of Acetylcholine, can itself activate nAChRs and thereby affects intrinsic and synaptic neuronal functions. Here, we asked whether the cellular actions of choline directly affect hippocampal network activity. Using mouse hippocampal slices we found that choline efficiently suppresses spontaneously occurring sharp wave-ripple complexes (SPW-R) and can induce gamma oscillations. In addition, choline reduces synaptic transmission between hippocampal subfields CA3 and CA1. Surprisingly, these effects are mediated by activation of both mAChRs and a7-containing nAChRs. Most nicotinic effects became only apparent after local, fast application of choline, indicating rapid desensitization kinetics of nAChRs. Effects were still present following block of choline uptake and are, therefore, likely because of direct actions of choline at the respective receptors. Together, choline turns out to be a potent regulator of patterned network activity within the hippocampus. These actions may be of importance for understanding state transitions in normal and pathologically altered neuronal networks.

show abstract

“…CSF levels of Ach (Duvoisin and Dettbarn, 1967; Welch et al, 1976; Yamada et al, 1996) and its precursor choline (Aquilonius et al, 1972; Welch et al, 1976; Nasr et al, 1993) have been reported to be similar in PD patients to controls with the exception of one study in which lower CSF choline levels were described in PD patients (Manyam et al, 1990). …”

Section: Neurotransmitters Neuromodulators and Related Substancesmentioning

confidence: 99%

“…CSF activity of acetylcholine-esterase (AchE), the main enzyme involved in Ach degradation, has been reported to be similar in PD patients and controls (Jolkkonen et al, 1986; Ruberg et al, 1986; Zubenko et al, 1986; Sirviö et al, 1987; Yoshinaga et al, 1989; Manyam et al, 1990; Hartikainen et al, 1992), although there are studies which have described increased (Ruberg et al, 1986), decreased (Konings et al, 1995), or normal activity (Zubenko et al, 1986; Sirviö et al, 1987) in demented patients, and decreased activity only in those patients with the most severe disease (Hartikainen et al, 1992). …”

Section: Neurotransmitters Neuromodulators and Related Substancesmentioning

confidence: 99%

Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease

Jiménez‐Jiménez¹,

Alonso‐Navarro

García‐Martín

et al. 2014

Front. Cell. Neurosci.

View full text Add to dashboard Cite

The blood-brain barrier supplies brain tissues with nutrients and filters certain compounds from the brain back to the bloodstream. In several neurodegenerative diseases, including Parkinson's disease (PD), there are disruptions of the blood-brain barrier. Cerebrospinal fluid (CSF) has been widely investigated in PD and in other parkinsonian syndromes with the aim of establishing useful biomarkers for an accurate differential diagnosis among these syndromes. This review article summarizes the studies reported on CSF levels of many potential biomarkers of PD. The most consistent findings are: (a) the possible role of CSF urate on the progression of the disease; (b) the possible relations of CSF total tau and phosphotau protein with the progression of PD and with the preservation of cognitive function in PD patients; (c) the possible value of CSF beta-amyloid 1-42 as a useful marker of further cognitive decline in PD patients, and (d) the potential usefulness of CSF neurofilament (NFL) protein levels in the differential diagnosis between PD and other parkinsonian syndromes. Future multicentric, longitudinal, prospective studies with long-term follow-up and neuropathological confirmation would be useful in establishing appropriate biomarkers for PD.

show abstract

Cerebrospinal fluid choline levels are decreased in Parkinson's disease

Cited by 21 publications

References 13 publications

Neurochemical markers in the cerebrospinal fluid of patients with Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis and normal controls

Neurochemical markers in the cerebrospinal fluid of patients with Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis and normal controls

Choline‐mediated modulation of hippocampal sharp wave–ripple complexes in vitro

Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease

Contact Info

Product

Resources

About